Galmed Pharmaceuticals (GLMD) Amortizatization of Intangibles (2015 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Amortizatization of Intangibles of $9000.0 for Q1 2026, down 73.53% year-over-year from $34000.0 in Q1 2025, and up 250.0% quarter-over-quarter from -$6000.0 in Q4 2025.
Galmed Pharmaceuticals (GLMD) Amortizatization of Intangibles (2015 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Amortizatization of Intangibles history runs 12 years deep, the most recent figure standing at $9000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 73.53% year-over-year to $9000.0; the TTM figure through Mar 2026 stood at -$10000.0 (down 122.73% YoY), while the FY2025 annual figure was $15000.0, up 188.24% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $9000.0, up from -$6000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $191000.0 in Q2 2023, with the low at -$176000.0 in Q1 2023.
- The 5-year median for Amortizatization of Intangibles is $5000.0 (2025), against an average of $3615.4.
- The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles plunged 1083.33% in 2022, then surged 4675.0% in 2023.
- Galmed Pharmaceuticals' Amortizatization of Intangibles stood at -$59000.0 in 2022, then surged by 106.78% to $4000.0 in 2023, then jumped by 50.0% to $6000.0 in 2024, then slumped by 200.0% to -$6000.0 in 2025, then jumped by 250.0% to $9000.0 in 2026.
- Business Quant data shows GLMD's Amortizatization of Intangibles at $9000.0 in Q1 2026, -$6000.0 in Q4 2025, and $5000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | 9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9,000.00 |
| Mar 31, 2026 | 9,000.00 |
| Dec 31, 2025 | -6,000.00 |
| Dec 31, 2025 | -6,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Jun 30, 2025 | -18,000.00 |
| Jun 30, 2025 | -18,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 191,000.00 |
| Jun 30, 2023 | 191,000.00 |
| Mar 31, 2023 | -176,000.00 |
| Mar 31, 2023 | -176,000.00 |
| Dec 31, 2022 | -59,000.00 |
| Dec 31, 2022 | -59,000.00 |